POSARD MATTHEW L. sold 24.4% of their position (19K shares) of HALOZYME THERAPEUTICS, INC. on the open market
Open‑market sale worth $2.05M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 9/17/2026ACC: 0001159036-26-000123
Director
Since May 2019
-19K
Net shares
Net seller
$2.05M
Total sold
4
Open market trades
0B · 4S
4
Total transactions
19K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−3.10K
Price / share
$106.13
Trade value
$329.01K
% of position
4.0%
9/16/2026
77.83K→74.73K
Common Stock
Direct
Shares
−3K
Price / share
$106.83
Trade value
$320.48K
% of position
4.0%
9/16/2026
74.73K→71.73K
Common Stock
Direct
Shares
−8.90K
Price / share
$108.04
Trade value
$961.12K
% of position
12.4%
9/16/2026
71.73K→62.84K
Common Stock
Direct
Shares
−4K
Price / share
$108.99
Trade value
$435.96K
% of position
6.4%
9/16/2026
62.84K→58.84K
Total
Net shares
−19K
Net value
-$2.05M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/16/2026 | S · Sale | −3.10K | $106.13 | $329.01K | 4.0% | 77.83K | 74.73K |
| Common Stock Direct | 9/16/2026 | S · Sale | −3K | $106.83 | $320.48K | 4.0% | 74.73K | 71.73K |
| Common Stock Direct | 9/16/2026 | S · Sale | −8.90K | $108.04 | $961.12K | 12.4% | 71.73K | 62.84K |
| Common Stock Direct | 9/16/2026 | S · Sale | −4K | $108.99 | $435.96K | 6.4% | 62.84K | 58.84K |
| Total | −19K | -$2.05M | ||||||
Derivative Transactions0
No derivative transactions reported